Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, placebo-controlled trial in 176 Korean subjects

S. Kang, K. H. Kim, Y. T. Kim, Y. T. Kim, J. H. Kim, Y. S. Song, S. H. Shin, H. S. Ryu, J. W. Han, J. H. Kang, S. Y. Park

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is a major causative agent of anogenital warts and a necessary cause of cervical cancer. This report will serve to assess the safety and immunogenicity of quadrivalent (types 6, 11, 16, and 18) HPV L1 virus-like particle (VLP) vaccine in the Korean population. We performed a randomized, double-blind, placebo-controlled study in 176 volunteers aged 9-23 years. Using a 2:1 ratio for randomization, 117 women were assigned to quadrivalent HPV (20 μg type 6, 40 μg type 11, 40 μg type 16, and 20 μg type 18) vaccine and 59 women to placebo. Individuals received vaccine at day 1, month 2, and month 6 and provided blood samples for analysis at enrollment at month 7. Analyses were done as specified in the study protocol. Quadrivalent HPV vaccine was generally well tolerated, with no vaccine-related serious adverse experiences. Quadrivalent HPV vaccine induced seroconversion for each vaccine-related HPV type. At month 7, vaccine-induced type-specific antibody titer was high. In conclusion, administration of quadrivalent HPV VLP vaccine to Korean women aged 9-23 years was generally well tolerated and highly immunogenic.

Original languageEnglish
Pages (from-to)1013-1019
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume18
Issue number5
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Human papillomavirus 11
Human papillomavirus 6
Papillomavirus Vaccines
Human papillomavirus 18
Papillomaviridae
Virus-Like Particle Vaccines
Vaccines
Randomized Controlled Trials
Placebos
Safety
Warts
Random Allocation
Uterine Cervical Neoplasms
Volunteers
Vaccine Immunogenicity
Antibodies
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Kang, S. ; Kim, K. H. ; Kim, Y. T. ; Kim, Y. T. ; Kim, J. H. ; Song, Y. S. ; Shin, S. H. ; Ryu, H. S. ; Han, J. W. ; Kang, J. H. ; Park, S. Y. / Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18 : A randomized, placebo-controlled trial in 176 Korean subjects. In: International Journal of Gynecological Cancer. 2008 ; Vol. 18, No. 5. pp. 1013-1019.
@article{1f13079b706f417aa226d7020059986a,
title = "Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, placebo-controlled trial in 176 Korean subjects",
abstract = "Human papillomavirus (HPV) is a major causative agent of anogenital warts and a necessary cause of cervical cancer. This report will serve to assess the safety and immunogenicity of quadrivalent (types 6, 11, 16, and 18) HPV L1 virus-like particle (VLP) vaccine in the Korean population. We performed a randomized, double-blind, placebo-controlled study in 176 volunteers aged 9-23 years. Using a 2:1 ratio for randomization, 117 women were assigned to quadrivalent HPV (20 μg type 6, 40 μg type 11, 40 μg type 16, and 20 μg type 18) vaccine and 59 women to placebo. Individuals received vaccine at day 1, month 2, and month 6 and provided blood samples for analysis at enrollment at month 7. Analyses were done as specified in the study protocol. Quadrivalent HPV vaccine was generally well tolerated, with no vaccine-related serious adverse experiences. Quadrivalent HPV vaccine induced seroconversion for each vaccine-related HPV type. At month 7, vaccine-induced type-specific antibody titer was high. In conclusion, administration of quadrivalent HPV VLP vaccine to Korean women aged 9-23 years was generally well tolerated and highly immunogenic.",
author = "S. Kang and Kim, {K. H.} and Kim, {Y. T.} and Kim, {Y. T.} and Kim, {J. H.} and Song, {Y. S.} and Shin, {S. H.} and Ryu, {H. S.} and Han, {J. W.} and Kang, {J. H.} and Park, {S. Y.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1111/j.1525-1438.2007.01123.x",
language = "English",
volume = "18",
pages = "1013--1019",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18 : A randomized, placebo-controlled trial in 176 Korean subjects. / Kang, S.; Kim, K. H.; Kim, Y. T.; Kim, Y. T.; Kim, J. H.; Song, Y. S.; Shin, S. H.; Ryu, H. S.; Han, J. W.; Kang, J. H.; Park, S. Y.

In: International Journal of Gynecological Cancer, Vol. 18, No. 5, 01.09.2008, p. 1013-1019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18

T2 - A randomized, placebo-controlled trial in 176 Korean subjects

AU - Kang, S.

AU - Kim, K. H.

AU - Kim, Y. T.

AU - Kim, Y. T.

AU - Kim, J. H.

AU - Song, Y. S.

AU - Shin, S. H.

AU - Ryu, H. S.

AU - Han, J. W.

AU - Kang, J. H.

AU - Park, S. Y.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Human papillomavirus (HPV) is a major causative agent of anogenital warts and a necessary cause of cervical cancer. This report will serve to assess the safety and immunogenicity of quadrivalent (types 6, 11, 16, and 18) HPV L1 virus-like particle (VLP) vaccine in the Korean population. We performed a randomized, double-blind, placebo-controlled study in 176 volunteers aged 9-23 years. Using a 2:1 ratio for randomization, 117 women were assigned to quadrivalent HPV (20 μg type 6, 40 μg type 11, 40 μg type 16, and 20 μg type 18) vaccine and 59 women to placebo. Individuals received vaccine at day 1, month 2, and month 6 and provided blood samples for analysis at enrollment at month 7. Analyses were done as specified in the study protocol. Quadrivalent HPV vaccine was generally well tolerated, with no vaccine-related serious adverse experiences. Quadrivalent HPV vaccine induced seroconversion for each vaccine-related HPV type. At month 7, vaccine-induced type-specific antibody titer was high. In conclusion, administration of quadrivalent HPV VLP vaccine to Korean women aged 9-23 years was generally well tolerated and highly immunogenic.

AB - Human papillomavirus (HPV) is a major causative agent of anogenital warts and a necessary cause of cervical cancer. This report will serve to assess the safety and immunogenicity of quadrivalent (types 6, 11, 16, and 18) HPV L1 virus-like particle (VLP) vaccine in the Korean population. We performed a randomized, double-blind, placebo-controlled study in 176 volunteers aged 9-23 years. Using a 2:1 ratio for randomization, 117 women were assigned to quadrivalent HPV (20 μg type 6, 40 μg type 11, 40 μg type 16, and 20 μg type 18) vaccine and 59 women to placebo. Individuals received vaccine at day 1, month 2, and month 6 and provided blood samples for analysis at enrollment at month 7. Analyses were done as specified in the study protocol. Quadrivalent HPV vaccine was generally well tolerated, with no vaccine-related serious adverse experiences. Quadrivalent HPV vaccine induced seroconversion for each vaccine-related HPV type. At month 7, vaccine-induced type-specific antibody titer was high. In conclusion, administration of quadrivalent HPV VLP vaccine to Korean women aged 9-23 years was generally well tolerated and highly immunogenic.

UR - http://www.scopus.com/inward/record.url?scp=51749098990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51749098990&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.01123.x

DO - 10.1111/j.1525-1438.2007.01123.x

M3 - Article

C2 - 17986242

AN - SCOPUS:51749098990

VL - 18

SP - 1013

EP - 1019

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -